It was notable that three individuals reported here with MMIHS due to apparent de novo mutations in ACTG2 reported clinical improvement on cisapride, a serotonergic 5HT4 agonist. Here, HTR4 is linked to megacystis-microcolon-intestinal hypoperistalsis syndrome 1.